These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Repetitive transcranial magnetic stimulation in patients with progressive supranuclear palsy: a pilot study. Santens P; Sieben A; De Letter M Acta Neurol Belg; 2009 Sep; 109(3):200-4. PubMed ID: 19902813 [TBL] [Abstract][Full Text] [Related]
24. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Antoni S; Ferger D; Reichmann H; Wilhelm H; Berg D; Ziemssen T Mov Disord; 2007 Oct; 22(14):2123-6. PubMed ID: 17853484 [TBL] [Abstract][Full Text] [Related]
25. A clinical rating scale for progressive supranuclear palsy. Golbe LI; Ohman-Strickland PA Brain; 2007 Jun; 130(Pt 6):1552-65. PubMed ID: 17405767 [TBL] [Abstract][Full Text] [Related]
26. [A 70-year-old man with a progressive gait disturbance and gaze palsy]. Nakamura T; Yoritaka A; Sumino S; Suzuki H; Mori H; Suda K; Takubo H; Mizuno Y No To Shinkei; 1997 Jan; 49(1):93-100. PubMed ID: 9027910 [TBL] [Abstract][Full Text] [Related]
27. Physostigmine challenge before and after chronic cholinergic blockade in elderly volunteers. Dukoff R; Wilkinson CW; Lasser R; Friz J; Conway A; Bahro M; Peskind ER; Sunderland T Biol Psychiatry; 1999 Jul; 46(2):189-95. PubMed ID: 10418693 [TBL] [Abstract][Full Text] [Related]
29. Gaze control and foot kinematics during stair climbing: characteristics leading to fall risk in progressive supranuclear palsy. Di Fabio RP; Zampieri C; Tuite P Phys Ther; 2008 Feb; 88(2):240-50. PubMed ID: 18073265 [TBL] [Abstract][Full Text] [Related]
36. Cholinergic approaches to the treatment of progressive supranuclear palsy. Litvan I J Neural Transm Suppl; 1994; 42():275-81. PubMed ID: 7964692 [TBL] [Abstract][Full Text] [Related]
37. [A clinical and epidemiological description of a series of patients diagnosed as suffering from progressive supranuclear palsy]. Alvarez-González E; Maragoto-Rizo C; Arteche-Prior M; Pérez-Parra S; Carballo M; Alvarez-González L Rev Neurol; 2004 Dec 1-15; 39(11):1006-10. PubMed ID: 15597260 [TBL] [Abstract][Full Text] [Related]
38. Cholinergic modulation of spatial working memory of mice in radial maze performance: retention curve analysis. Inagawa K Yakubutsu Seishin Kodo; 1993 Aug; 13(4):233-8. PubMed ID: 8237140 [TBL] [Abstract][Full Text] [Related]
39. Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat. Waters KA; Burnham KE; O'connor D; Dawson GR; Dias R J Psychopharmacol; 2005 Mar; 19(2):149-58. PubMed ID: 15728436 [TBL] [Abstract][Full Text] [Related]
40. [Comparison of the vesicourethral function between progressive supranuclear palsy and Parkinson's disease]. Wakatsuki A; Tsujihata M; Miyake O; Ito H; Itatani H; Udaka F Hinyokika Kiyo; 1993 Jun; 39(6):523-8. PubMed ID: 8337978 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]